# Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

> **NCT04698915** · PHASE2 · TERMINATED · sponsor: **Galera Therapeutics, Inc.** · enrollment: 177 (actual)

## Conditions studied

- SBRT
- Borderline Resectable Pancreatic Cancer
- Unresectable Pancreatic Cancer

## Interventions

- **DRUG:** Drug GC4711
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04698915
- **Lead sponsor:** Galera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-07
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 177 (ACTUAL)
- **Why stopped:** Futility Analysis
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04698915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04698915, "Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04698915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*